Johnson & Johnson (JNJ) said the company expects fiscal 2025 adjusted EPS in a range of $10.50 - $10.70, which represents a growth of 6.2%, at midpoint. Adjusted operational EPS is estimated in a range of $10.75 - $10.95, which represents a growth of 8.7%, at midpoint. Johnson & Johnson noted that its guidance excludes impact from the recently announced acquisition of Intra-Cellular Therapies Inc. The anticipated impact from planned ITCI acquisition is in a range of $0.30 - $0.35 to 2025 adjusted earnings results. Analysts on average expect the company to report profit per share of $10.60. Analysts' estimates typically exclude special items.
For fiscal 2025, the company expects reported sales in a range of $89.2 billion - $90.0 billion. Operational sales are estimated in a range of $90.9 billion - $91.7 billion. Adjusted operational sales are projected to rise 2.5%, at mid-point of guidance range.
For comments and feedback: editorial@rttnews.com